Release announcement:

Cleerly Labs v2.2.0

 

MA_Minute-Vol01-Hero_Image

Cleerly is on a mission to create a world without heart attacks.

Our team is excited to share our new release with features that track disease progression, understand disease amount, identify dangerous plaque, and automate study workflows.

 

Track Disease Progression 

Cleerly's new first-of-its-kind comparison tool tracks patient disease rather than surrogates over time, helping evaluate the efficacy of treatment success.

cleerly_2_2_0-compare_tool_extended

cleerly_2_2_0-PAV

 

Understand Disease Amount

Cleerly's Percent Atheroma Volume (PAV) quantifies the amount of plaque as a percentage of the total vessel volume, making it easier for patients to understand disease amount.

 

Automated Study Workflow

Cleerly's new version of Ambra Workflow Optimization enhances automation of study transfers by limiting efforts if uploads are paused for any reason.

 

cleerly_2_2_0-ambra_optimization

 

Cleerly Labs v2.2.0 Release Notes:
  • Study comparison functionality
  • Editing tool expansion - Thresholding & Epicardial Fat tools
  • Additional outputs –  Percent Atheroma Volume (PAV) and exclusion outputs
  • Image viewing – Maximum Intensity Projection (MIP) functionality & larger cross-section layout
  • Layout updates to the downloadable reports
  • Policy acceptance requirements
  • Textual summary updates
  • Bug fixes

READY TO LEARN MORE?

 
Schedule a demo with us to explore Cleerly and how you can leverage our technology to improve patient care.
Patents

Cleerly continues to revolutionize heart attack and cardiovascular disease prevention and treatment everyday by inventing world-class technology. Cleerly invests significant time and resources in research and development towards this goal. To protect Cleerly’s research and development efforts, Cleerly has vigorously developed a robust intellectual property portfolio – all part of a strategy for protecting the innovations that make Cleerly an industry leader in cardiovascular disease prevention and treatment.

Cleerly’s products and services may be covered by or for use under one or more of U.S. Patent Nos. 11,922,627, 11,948,301, 12,023,190, 11,861,833, 11,967,078, 11,832,982, 11,690,586, 11,779,292, 11,730,437, 11,672,497, 11,737,718, 11,751,826, 11,660,058, 11,896,415, 11,751,830, 11,751,829, 11,302,001, 11,308,617, 11,238,587, 11,302,002, 11,321,840, 11,341,644, 11,244,451, 11,288,799, 11,276,170, 11,210,786, 11,232,564, 11,367,190, 11,315,247, 11,969,280, 11,094,060, 11,120,550, 11,120,549, 11,132,796, 11,094,061, 11,113,811, 11,501,436, 11,751,831, 11,642,092, 11,759,161, 11,317,883, 11,350,899, 11,766,230, 11,766,229, and 10,813,612, as well as other patents that are pending.

For additional information, please contact legal@cleerlyhealth.com.

Solutions
About

© 2024 Cleerly, Inc.